Eli Lilly & CO LLY
We take great care to ensure that the data presented and summarized in this overview for ELI LILLY & Co is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LLY
View all-
Pnc Financial Services Group, Inc. Pittsburgh, PA101MShares$79.7 Billion44.13% of portfolio
-
Lilly Endowment Inc Indianapolis, IN96MShares$75.6 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA79.2MShares$62.3 Billion1.22% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$51.8 Billion1.37% of portfolio
-
State Street Corp Boston, MA34.4MShares$27.1 Billion1.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD19.1MShares$15.1 Billion1.95% of portfolio
-
Geode Capital Management, LLC Boston, MA18.5MShares$14.6 Billion1.23% of portfolio
-
Capital World Investors Los Angeles, CA18.4MShares$14.5 Billion2.57% of portfolio
-
Capital Research Global Investors Los Angeles, CA15.7MShares$12.4 Billion2.95% of portfolio
-
Morgan Stanley New York, NY14.9MShares$11.7 Billion0.9% of portfolio
Latest Institutional Activity in LLY
Top Purchases
Top Sells
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Insider Transactions at LLY
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 16
2025
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
18
+0.11%
|
$14,526
$807.58 P/Share
|
Jun 16
2025
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.23%
|
$4,842
$807.58 P/Share
|
Jun 16
2025
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.61%
|
$9,684
$807.58 P/Share
|
Jun 16
2025
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
14
+0.03%
|
$11,298
$807.58 P/Share
|
Jun 16
2025
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.02%
|
$9,684
$807.58 P/Share
|
May 27
2025
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Open market or private sale
|
Direct |
1,000
-17.13%
|
$716,000
$716.41 P/Share
|
May 19
2025
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.23%
|
$4,530
$755.11 P/Share
|
May 19
2025
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.03%
|
$11,325
$755.11 P/Share
|
May 19
2025
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.02%
|
$9,815
$755.11 P/Share
|
May 19
2025
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.66%
|
$9,815
$755.11 P/Share
|
May 19
2025
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
19
+0.12%
|
$14,345
$755.11 P/Share
|
May 14
2025
|
Ilya Yuffa EVP & President, LLY Int'l |
SELL
Open market or private sale
|
Direct |
1,250
-4.35%
|
$936,250
$749.24 P/Share
|
May 02
2025
|
Anat Hakim EVP, GC & Secretary |
SELL
Bona fide gift
|
Direct |
17,875
-61.99%
|
-
|
Apr 21
2025
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
18
+0.11%
|
$14,724
$818.02 P/Share
|
Apr 21
2025
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.23%
|
$4,908
$818.02 P/Share
|
Apr 21
2025
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.02%
|
$9,816
$818.02 P/Share
|
Apr 21
2025
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.62%
|
$9,816
$818.02 P/Share
|
Apr 21
2025
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
14
+0.03%
|
$11,452
$818.02 P/Share
|
Mar 17
2025
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
17
+0.1%
|
$14,008
$824.76 P/Share
|
Mar 17
2025
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.23%
|
$4,944
$824.76 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 133K shares |
---|---|
Exercise of conversion of derivative security | 69.1K shares |
Open market or private sale | 937K shares |
---|---|
Payment of exercise price or tax liability | 30.9K shares |
Bona fide gift | 56.9K shares |